Arfolitixorin animation

Arfolitixorin animation

The animation explains how arfolitixorin works in cancer cells, describing the mechanism of action.

Arfolitixorin is Isofol’s proprietary drug candidate and is currently being evaluated in a global clinical phase 3 study in patients with advanced colorectal cancer. As the key active metabolite of the widely used folate-based drugs, arfolitixorin can potentially benefit all patients with advanced colorectal cancer, as it does not require complicated metabolic activation to become effective.